Studies Show that Parasitic Mites on the Eyes Contribute to Eyelid Inflammation, Including Ocular Rosacea; Two Top Eye Doctors Explain that Avenova Lid & Lash Hygiene can Help Ameliorate the Health of the Eyelids in Patients with this Common form of Blepharitis

MINNEAPOLIS, MN / ACCESSWIRE / March 28, 2017 / Dr. Richard L. Lindstrom, founder and attending surgeon of Minnesota Eye Consultants, and Dr. Ahmad Fahmy, immediate past director of Optometric Services at Minnesota Eye Consultants, today are making a public service announcement about the problem of eyelid inflammation and how this common eye condition can be managed with Avenova Lid & Lash Hygiene from NovaBay Pharmaceuticals (NYSE MKT: NBY).

Millions of Americans – up to 6% of the population – suffer from ocular rosacea, an inflammation that causes redness, burning, and itching of the eyes, explains Dr. Lindstrom and Dr. Fahmy. A clinical study has identified one important contributor: parasites called Demodex mites that infest the skin around the eyes and the eyelids and that carry bacteria like Bacillus oleronius. “This pivotal study showed that the bacterium carried by the mites stimulates an immune response that can often be uncomfortable,” says Dr. Fahmy. “The study also showed that patients may suffer from inflammatory reactions to the release of a large load of Bacillus antigens after the death of the mites.”

The authors of the study noted that, because this eye condition is exacerbated by mites and their associated bacteria, it is effectively treated by decreasing the mite count and the microbial symbiote.

Avenova is the only eye hygiene product to contain Neutrox, a pure 0.01% solution of hypochlorous acid. Hypochlorous acid is a substance naturally made by our own immune system as a first defense against invaders. Lab tests have shown that Neutrox kills bacteria and neutralizes the toxins bacteria produce, making it a key component in a comprehensive treatment for Demodex blepharitis.

“We’ve had excellent results with our own patients,” says Dr. Lindstrom. “Wiping eyes twice daily with Avenova sprayed on a cotton pad can
bring quick relief from ocular rosacea, as well as other conditions like blepharitis and dry eye.”

Contact:

Dr. Ahmad Fahmy, OD, FAAO, Minnesota Eye Consultants, P.A.; amfahmy@mneye.com; 612-813-3600
Dr. Richard L. Lindstrom, M.D., Minnesota Eye Consultants, P.A.; rllindstrom@mneye.com; 952-888-5800

SOURCE: NovaBay Pharmaceuticals

ReleaseID: 458295

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / These two stocks posted gains on Monday as they are likely to reduce losses going ahead. Both companies also moved forward with the FDA trials as their lead candidates advanced to Phase II (a).

RDI Initiates
Coverage:

BioDelivery Sciences
International, Inc. https://ub.rdinvesting.com/news/?ticker=BDSI

Rexahn
Pharmaceuticals, Inc. https://ub.rdinvesting.com/news/?ticker=RNN

BioDelivery Sciences International went up 8.57% to close at $1.90 on Monday. The stock traded between $1.90 and $1.76 on volume of 409,980 shares traded. The company, which develops pharmaceutical products that are primarily focused in the medical areas of pain management and addiction, has been trading at a relatively even level over the past 5 trading days. As the stock’s price has remained relatively steady over the last five days, investors are hoping for some type of insider trading activity or other sign that the stock is prepared to make a consistent upwards move.

The company’s total net revenue as reported on March 17th of this year, is in a best way comparable from a quarter-to-quarter comparison, as one time milestone payment from Endo significantly popped up its revenue in the same quarter last year. For the three-months ended December 31, 2016, its revenue was $3.9 million compared to $3.6 million for the quarter ended September 30, 2016. This slight loss is more representative of the company’s financials, as it has reported $30 million of total $50 million payment in fourth quarter of 2015 for reaching the BELBUCA-related FDA approval milestone. BioDelivery has reported significant increase in products sales in the year 2016 as compared to those of year 2015 and with the reacquisition of worldwide rights of BELBUCA from Endo, BioDelivery looking to increase revenue and to bring its commercial operations to profitability. BioDelivery has also secured $75 million in debt financing from CRG to strengthen cash balance on their books.

Access RDI’s BioDelivery Sciences Research Report at: https://ub.rdinvesting.com/news/?ticker=BDSI

Rexahn Pharmaceuticals advanced 13.33% to close at $0.51 on Monday. The stock traded between $0.52 and $0.44 per share on volume of 7,032,752 shares traded. The stock’s daily trading graph mimics its 90 day trading graph, as it has shown consistent resiliency despite some bumps. Yesterday, the company released its 4th quarter financials, which revealed that the company lost from operations was $16.4 million, a reduction of $1.9 million from 2015.

For its ongoing FDA drug trial candidates, the company reported that 4 of its drugs were entering Phase 2 protocols: RX-3117 for pancreatic cancer, Archexin to treat renal cell carcinoma, RX-3117 used in advanced cases of bladder cancer, and has begun a regimen of its trademarked drug Supinoxin in treating breast cancer.

Access RDI’s Rexahn Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=RNN

Our Actionable Research on BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458315

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / As FDA Phase trials continue, the two biopharmaceutical companies received positive feedback from the FDA and investors responded by adding shares of stock to their portfolios. Both companies’ stock rose to double digit percentages on the trading day.

RDI Initiates
Coverage:

Catalyst
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=CPRX

ZIOPHARM Oncology Inc. https://ub.rdinvesting.com/news/?ticker=ZIOP

Catalyst Pharmaceuticals began liftoff as its stock price rose 18.24 % to close at $2.01 on Monday. The stock traded between $2.065 and $1.63 on volume of 4,485,126 shares traded. On March 15th, the company reported successful top-line results from MuSK-MG trial, an investigator-sponsored, proof of concept trial evaluating Firdapse which treats patients afflicted with myasthenia gravis. The condition, which is an autoimmune neuromuscular disease, that only affects a patient’s voluntary muscle movement, is the result of a breakdown in a person’s normal communication process between nerves and muscles.

On March 15th when the company reported its 4th quarter and full year 2016 financials, it had a net loss of $18.1 million for the whole year of 2016, which was $2.1 million less than it had reported a year ago. R&D expenses were reduced by roughly $500,000, $11.37 million, in 2016 compared to $11.8 million reported in year 2015. Catalyst had $40.4 million cash available on its books as on December 31st, 2016.

Access RDI’s Catalyst Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=CPRX

ZIOPHARM Oncology advanced 13.78% to close at $6.69 on Monday. The stock traded between $6.89 and $5.79 on volume of 4,775,772 shares traded. News of the company’s successful end-of-phase meeting with the for its Phase 2 trial of Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma sparked the stock’s consistent rise throughout the day. ZIOPHARM received positive guidance from the FDA and was encouraged to continue its development of its lead candidate drug.

In corporate news, the company announced the appointment of Amy Trevvett as the Vice President of Investor Relations and Corporate Communications. Ms. Trevvett was brought in to increase the level of transparency of the company’s operations to investors, as Caesar Belbel, Executive Vice President, COO, and Chief Legal Officer said, “As part of our focus on communications with our shareholders and the investment community, we will be hosting quarterly conference calls beginning this May, in conjunction with our first quarter 2017 earnings report.”

Access RDI’s ZIOPHARM Oncology Research Report at: https://ub.rdinvesting.com/news/?ticker=ZIOP

Our Actionable Research on Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458314

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / Two biotech sector stocks made splashes of a different kind on Monday. Cellect had reported a very successfully performed stem cell transplant on first patient in a Phase I/II, proof of concept study, while Impax made an announcement by adding a critical top management appointment to direct the company into the future.

RDI Initiates
Coverage:

Cellect Biotechnology
Ltd. https://ub.rdinvesting.com/news/?ticker=APOP

Impax Laboratories
Inc. https://ub.rdinvesting.com/news/?ticker=IPXL

Cellect Biotechnology investors had to be elated when they saw the company’s stock shoot up 73% to close at $10.90 on Monday. The stock traded between $13.50 and $8.55 during the day, on a total volume of 9,124,841 shares traded. The news behind the stock move was the company’s announcement of its first successful stem cell transplant in a first cancer patient of Phase I/II study. The proof of concept ApoGraft01 study, designed to prevent life threatening graft-versus-host-disease (GvHD) disease, will enroll total of 12 patients for the study. Encouraging result in a first patient of this initial study is very hopeful and if Cellect technology turns out to be a viable workaround, Cellect can potentially become a major influence in the stem cell transplant arena and in the treatment of cancer. However, it will take about 5 or 6 years for Cellect to use “ApoGraft” for commercial purpose, provided they pass through all stages successfully. The patient was suffering with blood cancer.

Biotech investors should take note of the statement from Dr. Shai Yarkoni, Cellect’s CEO – “After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions.” Biotech successes may take a long time but there are huge potential rewards down the line. Though only one patient has successfully responded to the treatment, the Data and Safety Monitoring Board approved two additional patients to receive the ApoGraft(TM) treatment. Once those results are in it will complete first study cohort.

Access RDI’s Cellect Biotechnology Research Report at: https://ub.rdinvesting.com/news/?ticker=APOP

Impax Laboratories advanced 37.30% to close at $12.70 on Monday. The stock traded between $13.00 and $10.50 on volume of 12,382,067 shares traded. The surge in stock price of $3.45 came on the news that the company’s Board of Directors has appointed Paul M. Bisaro, to be President and CEO of Impax. The decision is clearly a vote of investor confidence in the track record of success of Mr. Bisaro. A middling 56 years old, he has amassed 25 years of experience with generic and branded pharmaceutical companies.

At the beginning of the month, Impax was being considered as one of the stocks in the Biotech and Pharmaceutical industries that would likely benefit from the deregulation approach by the new White House Administration. The company’s 4th quarter financials showed weakness, as its revenues decreased 29.7% to $198.4 million as compared to revenues of $282.09 million reported in the 4th quarter of 2015, as products from its generic division faced stiff competition and pricing pressure and resulting in revenue drop from generic division by nearly 39% year-on-year, in the 4th quarter. Investors’ optimism on the appointment of Mr. Paul M. Bisaro is by and large justified, given that the significant decline in revenue from Impax’s generic division in the last result, the road ahead, however, will not be smooth.

Access RDI’s Impax Laboratories Research Report at: https://ub.rdinvesting.com/news/?ticker=IPXL

Our Actionable Research on Cellect Biotechnology Ltd. (NASDAQ: APOP) and Impax Laboratories Inc. (NASDAQ: IPXL) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458313

LOS ANGELES, CA / ACCESSWIRE / March 28, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Patriot National, Inc. (“Patriot National” or the “Company”) (NYSE: PN) concerning possible violations of federal securities laws between August 15, 2016 and March 3, 2017, inclusive (the “Class Period”). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the firm by the May 15, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Patriot National made materially false and misleading statements and/or failed to disclose that: the Company’s special committee was beholden to CEO, Steve Mariano, therefore the special committee was operating for the benefit of Mariano and not Patriot National or its shareholders; that the special committee did not independently assess the merits of the Ebix transaction; that the special committee was not exploring strategic alternatives in order to maximize shareholder value; and that as a result of the above, Patriot’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 458347

NEW YORK, NY / ACCESSWIRE / March 28, 2017 /
Biotech stocks started the day unsurprisingly on a high today (Monday 28), with the collapse of Trumpcare bringing with it certainty in the market. The best performing ETF; the SPDR Health Care Sector saw a 0.27% rise, with 47 of the 60 equity components quickly catching up.

RDI Initiates
Coverage:

Cara Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=CARA

Corbus
Pharmaceuticals Holdings Inc. https://ub.rdinvesting.com/news/?ticker=CRBP

Cara Therapeutics’ share price increased by 0.42% during today’s trading session and is currently trading at $16.76. Things are looking good for the biotech company, with its market capitalization currently standing at $457.6 million. In the last fiscal year, the company experienced one of the most dramatic comebacks in its history, to record a $9 million profit last year.

The share price, however, has been on an upward trend rising from an all-year low of $4.35 and an all-time high of 19.44% per share. Investors are currently holding 423.7 million worth of shares, with an average of 1 million being traded daily. Today’s session saw trading almost break the 2 million mark, to trade at 1.7 million.

It is one of the most consistent stock prices in the industry, and now would be a great time to consider including it in your portfolio.

Access RDI’s Cara Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=CARA

The premarket trade on Monday saw Corbus Pharmaceuticals’ shares close the day 5.49% higher than the previous day’s results. The stock price saw its stock price increase by an impressive 114% since 2014 when the company first traded in the stock market.

The trial of Resunab, for the treatment of diffuse cutaneous systemic sclerosis completed the second phase of its trial late last week. The SPDR S&P Pharmaceuticals ETF dipped 19% and the S&P 500 SPX soared 5.9% during today’s trading session.

The company has recently announced its intentions to enter the next phase of developing Resunab, a treatment drug for systematic connective tissue disease.

Access RDI’s Corbus Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=CRBP

Our Actionable Research on Cara Therapeutics Inc. (NASDAQ: CARA) and Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458323

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / Superconductor Technologies and Gevo have both been acknowledged for their innovation – one company being awarded a patent, the other being recognized by a distinguished group of peers. Both companies will be releasing their 4th quarter and year-end financials this week, giving investors hope the notoriety will translate into future earnings.

RDI Initiates
Coverage:

Superconductor
Technologies, Inc. https://ub.rdinvesting.com/news/?ticker=SCON

Gevo, Inc. https://ub.rdinvesting.com/news/?ticker=GEVO

Superconductor Technologies advanced 19.38% to close at $1.54 on Monday. The stock traded between $1.65 and $1.29 on volume of 4,808,008 shares traded. Several factors spurred the price of the technology company. On February 21st, it had been awarded a patent for a key feature of the RCE-CDR system. The patent, U.S. Patent No. 9,567,661 named “Reactor Device With Removable Deposition Monitor” will improve cycle time, create higher throughput, and lower overall costs. Prior to this, on February 16th, the company also received patents No. 9,564,258 for unique wire manufacturing process. The company will announce its 4th quarter and year-end 2016 financial results prior to the market opening on Tuesday, March 28th. Later in the day, there will be a follow up with a scheduled conference call to be held at 11:00 ET to discuss the results.

Access RDI’s Superconductor Research Report at: https://ub.rdinvesting.com/news/?ticker=SCON

Gevo advanced 13.27% to close at $1.28 on Monday. The stock traded between $1.30 and $1.10 on volume of 3,126,891 shares traded. The stock is in the news as the company’s planned release of 4th quarter financials on the afternoon of March 29th at 4:30 EDT. The second is connected to the first, which involves the company’s announcement back on March 6th of this year that “The Digest,” a global bioeconomy daily publication that is the industry’s most widely read publication, had awarded Gevo the number 10 rank in its 2017 edition. The special section, titled, “50 Hottest Companies in the Advanced Bioeconomy”, arrives at its rankings by the selection of a prestigious group of specialists in the industry. Gevo specializes in the development and marketing of alternatives to petroleum-based products and it has recently raised $11.9 million by offering common stocks and warrants to strengthen its balance sheet.

Access RDI’s Gevo Research Report at: https://ub.rdinvesting.com/news/?ticker=GEVO

Our Actionable Research on Superconductor Technologies, Inc. (NASDAQ: SCON) and Gevo, Inc. (NASDAQ: GEVO) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458317

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / Halliburton and Weatherford both made announcements yesterday that will impact their first quarter financial reports to investors. They both are experiencing expansion and growth, but there is a short term price to pay that investors will have to be patient with to see how things look at the end of the year.

RDI Initiates
Coverage:

Halliburton Company https://ub.rdinvesting.com/news/?ticker=HAL

Weatherford
International Plc https://ub.rdinvesting.com/news/?ticker=WFT

Halliburton stock closed down 3.30% to settle at $47.78 on Monday. The stock traded between $48.77 and $47.52 on volume of 14,193,715 shares traded. The downturn is part of a general market reaction to the uncertainty of the economy after the collapse of the proposed health care legislation. The news that more directly impacted the stock price occurred yesterday during a scheduled conference call/webcast to update the 4th quarter company operational plan. In that call, Halliburton, the oilfield service giant, said it would be incurring the projected operational expenses for the entire year into the first 6 months of the year. The reason for this was the increase in demand for Halliburton rigs, which is currently at a pace of almost 2 per day, requires the outlay of the operational expenses. In addition to the operation costs, the company will be hiring almost 2,000 field employees in the Unites States alone as it expects 25 percent increase in revenue from US land operation in the current quarter from those reported in fourth quarter last year, but the hiring will add to the costs and will impact 1st quarter profits and giving it a miss. An unexpected contract in the Gulf of Mexico has been another event that adds to the impact the expected single digit earnings per share cost of Halliburton’s reported first quarter financial results. Despite yesterday’s news and price drop, the stock began recovering in after hours trading.

Halliburton has been reducing its debt consistently and it has announced redemption of senior notes totaling $1.4 billion in the current quarter. The company has received large numbers of “buy” ratings from different analysts, and recently Deutsche Bank reiterated “buy” ratings on the company on 27th March, and couple of “buy” or “overweight” ratings were also assigned from other investment research firms during the month of March.

Access RDI’s Halliburton Research Report at:
https://ub.rdinvesting.com/news/?ticker=HAL

Weatherford International ended the day moving up 7.98% to close at $6.36 on Monday. The stock traded between $6.51 and $6.25 on volume of 36,798,144 shares traded. Recently it announced a joint venture with Schlumberger that will result in 70% of Weatherford’s onshore resources being owned, operated, and consolidated by Schlumberger. In addition to the properties, Weatherford will get a payment in the amount of $535 million once the deal is finalized, which is expected to be completed in the fourth quarter of this year. The joint venture will be called OneStim.

Weatherford stock has had its ups and downs to start the year, closing at $5.18 on February 1st of this year.

Access RDI’s Weatherford Research Report at:
https://ub.rdinvesting.com/news/?ticker=WFT

Our Actionable Research on Halliburton Company (NYSE: HAL) and Weatherford International Plc (NYSE: WFT) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458316

ZURICH, SWITZERLAND / ACCESSWIRE / March 28, 2017 / About 2 months ago, Pistol Bay Mining Inc. (TSX-V: PST) reported that mining giant Rio Tinto has started to drill 4-6 holes on the C5 uranium property in the prolific Athabasca Basin. Today, Pistol Bay announced to have entered into an amending agreement with Rio Tinto Exploration Canada Inc. with regard to the C 4, 5, and 6 Uranium properties, whereby Rio Tinto will make an initial cash payment of $750,000 to Pistol Bay within the next 3 weeks.

Under the amending agreement, Rio Tinto will acquire an additional 25% interest in the Property (thereby increasing its aggregate interest to 100%), by:

(a) paying Pistol Bay $750,000 on or before April 17, 2017; and

(b) paying Pistol Bay one of the following payments:
(i) $1,500,000 on or before 31 December 2017;
(ii) $2,000,000 on or before 31 December 2018; or
(iii) $2,250,000 on or before 31 December 2019.

Pistol Bay will retain a 5% net profits interest in the Property.

Charles Desjardins, CEO of Pistol Bay, commented today:

“Rio Tinto’s payment does not dilute the Company and allows Pistol Bay to expand the scope of its upcoming exploration work, including drilling, on its Confederation Lake greenstone belt zinc-copper-gold project. We look forward to continuing our working relationship with Rio Tinto.”

The full report can be accessed with the following links:

English (PDF): http://rockstone-research.com/images/PDF/PistolBay5en.pdf

English (web version):
http://rockstone-research.com/index.php/en/research-reports/2801-Rio-Tinto-injects-cash-into-Pistol-Bay

German (PDF): http://rockstone-research.com/images/PDF/PistolBay5de.pdf

Disclaimer: Please read the full disclaimer within the full research report as a PDF as fundamental risks and conflicts of interest exist.

SOURCE: Rockstone Research

ReleaseID: 458346

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / GoPro’s share price has plummeted amid fears of a failing business strategy. Despite everything looking grey, the company holds a significant portion of the market share, with Garmin and Eastman Kodak coming closest. Fitbit is going global with its wristband apparel, Alta HR Fitness wristband. Their stock price is facing north and moving in the same direction. Marred by a disappointing sale of its first rollout of hardware since the company went public, Fitbit is yet to see its glory days. Here’s how the two stocks performed today.

RDI Initiates
Coverage:

Fitbit Inc. https://ub.rdinvesting.com/news/?ticker=FIT

GoPro Inc. https://ub.rdinvesting.com/news/?ticker=GPRO

Fitbit’s shares closed the day on a high, registering a 5.37% growth in the stock price. The stocks opened at 5.33, with the price ranging from 5.31 to 5.74 percentile. With the volume of trade almost hitting the $10 million mark, and a negative EPS, there is still reason to predict an upward trend as the week is just but beginning. The tech company’s recent global penetration and expansion ambition saw the shares plummet from the 52 week high of 18.85, but there is no reason for concern as the sales volume are going up day by day.

Access RDI’s Fitbit Research Report at: https://ub.rdinvesting.com/news/?ticker=FIT

GoPro has enjoyed an impressive run since last week. Going by the current trend, everything looks green. The company started the day’s trade at $8.30, with a day’s range of -0.08 low and +0.33 to finally close at 8.43, a 1.57% increase. The action camera tech company has a stronger image and a more identifiable brand than its closest competitors. The company however expects competition from better funded companies like Samsung in its virtual reality and 360 degrees camera line of products.

Investors are highly anticipating a better response from GoPro, with the competition being well funded and with an almost similar line of product. The “best in the business” notion the company is currently riding on might not hold water for too long though.

Access RDI’s GoPro Research Report at: https://ub.rdinvesting.com/news/?ticker=GPRO

Our Actionable Research on Fitbit Inc. (NYSE: FIT) and GoPro Inc. (NASDAQ: GPRO) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458327